PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104650
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104650
Extracorporeal Co2 Removal Devices market size was valued at US$ 150.8 Million in 2025, expanding at a CAGR of 8.8% from 2026 to 2033.
Extracorporeal CO2 removal (ECCOR), also known as ECCO2R, refers to minimally invasive systems that deliver respiratory support through the withdrawal of CO2 from the blood, resulting in reduced strain on the injured lung, through a gas exchange unit that is situated outside the body. The machine uses a vascular access catheter for blood removal and return catheters for blood return after it has been purified by pumping it through a gas exchange membrane. These devices have a significant function in enhancing respiratory management.
Extracorporeal Co2 Removal Devices Market- Market Dynamics
Rising Cases of Severe Respiratory Conditions to Boost Market Expansion
The rising incidence of severe respiratory disorders is mainly driven by the growing number of patients suffering from COPD, ARDS, and other critical respiratory illnesses that require more advanced respiratory assistance. For instance, in June 2025, according to the UK government's Respiratory Disease Profile statistical commentary, there have been emergency hospital admissions at hospital sites in England that have amounted to 854,922 admissions, which is an increase in crude admission rate to 1,428 admissions per 100,000 population compared to the previous year, while admissions for COPD increased by 9% to 121,129 admissions compared to the previous year, and the number of admissions related to asthma in adults (over 19 years old) increased by 17% to 41,367 admissions in the same period. This growing clinical burden is accelerating the demand for advanced extracorporeal CO2 removal devices in critical care settings.
The Global Extracorporeal Co2 Removal Devices market is segmented on the basis of Product, Application, Access, End Use, and Region.
In terms of product type, extracorporeal CO2 machines represent a significant portion because such revolutionary machines have started being widely utilised in order to achieve efficient removal of CO2 in critical care settings, especially in patients experiencing severe respiratory failure. In July 2025, Medtronic obtained CE mark approval of its VitalFlow(TM) ECMO System, adding to its range of extracorporeal life support solutions, adding to its critical care devices range, and developing highly advanced life support devices that can be used in combination with respiratory extracorporeal therapies. Hence, the global market for such advanced extracorporeal CO2 machines will certainly witness an upward trend.
Extracorporeal Co2 Removal Devices Market- Geographical Insights
North America is witnessing strong growth in ECCO2R because of growing clinical acceptance within specialised care settings. For example, during Dec 2025, as per the data released by the Association of American Medical Colleges (Org.), the total number of enrolments in the US MD-granting medical colleges stood at 100,723 students for the 2025/26 academic year. This marks the first time in which the total enrolment went above 100,000. The data showed that there was an increase in the number of people who applied to medical school by 5.3%, of whom 76.5% were first-time applicants, with an increase of 8.4%. There are some signs of increased clinical acceptance with the increased participation in medical education programmes. This expanding clinical workforce is expected to support broader adoption of ECCO2R technologies across advanced healthcare settings.
The extracorporeal CO2 removal devices market in Asia Pacific is expanding due to the rise in the incidence of respiratory diseases, increasing pollution levels, and the growing demand for critical care products. For instance, in May 2026, according to the Commonwealth Fund's Org Japan health system profile, Japan has one of the most advanced health infrastructures. Also, 'Japan's advanced health infrastructure makes it possible for the country to provide 1,191 hospital beds per 100,000 individuals, or 1,450,322 beds in total. The country also has a public insurance scheme that provides 100 per cent coverage and accounts for 10.7 per cent of GDP. These developments will also stimulate sales for the extracorporeal CO2 removal device market in the Asia-Pacific region.
The Extracorporeal Co2 Removal Devices market is highly competitive, with leading companies such as Medtronic, Getinge AB, Xenios AG, LivaNova PLC, and Terumo Corporation driving industry growth. Various strategies that include the gaining of a competitive advantage and meeting the customer needs through various ways, including product launch, collaborations, and geographical expansions, have been taken up by various firms. In March 2026, Getinge acquired the CE mark for the Cardiohelp II ECLS platform and introduced the next generation of its platform, which would be smarter and more connected than its previous version and would provide better clinical support for ECMO and ECCO2R applications. These strategic initiatives are expected to enhance technological advancements and strengthen competitive positioning across the global market.
In October 2025, Terumo acquired OrganOx. With this move, the company expanded its offerings into organ preservation technology and strengthened its future plans to develop medical technologies related to extracorporeal life support and transplantation.